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Abstract

Author Manuscript

Nicotine is a psychomotor stimulant with ‘reinforcement enhancing’ effects – the actions of
nicotine in the brain increase responding for non-nicotine rewards. We hypothesized that this latter
effect of nicotine depends on increased incentive properties of anticipatory cues; consistent with
this hypothesis, multiple laboratories have reported that nicotine increases sign tracking, i.e.
approach to a conditioned stimulus (CS), in Pavlovian conditioned-approach tasks. Incentive
motivation and sign tracking are mediated by mesolimbic dopamine (DA) transmission and
nicotine facilitates mesolimbic DA release. Therefore, we hypothesized that the incentivepromoting effects of nicotine would be impaired by DA antagonists. To test this hypothesis,
separate groups of rats were injected with nicotine (0.4 mg/kg base) or saline prior to Pavlovian
conditioning sessions in which a CS (30 s illumination of a light or presentation of a lever) was
immediately followed by a sweet reward delivered in an adjacent location. Both saline and
nicotine pretreated rats exhibited similar levels of conditioned approach to the reward location
(goal tracking), but nicotine pretreatment significantly increased approach to the CS (sign
tracking), regardless of type (lever or light). The DAD1 antagonist SCH-23390 and the DAD2/3
antagonist eticlopride reduced conditioned approach in all rats, but specifically reduced goal
tracking in the saline pretreated rats and sign tracking in the nicotine pretreated rats. The nonselective DA antagonist flupenthixol reduced sign-tracking in nicotine rats at all doses tested;
however, only the highest dose of flupenthixol reduced goal tracking in both nicotine and saline
groups. The reductions in conditioned approach behavior, especially those by SCH-23390, were
dissociated from simple motor suppressant effects of the antagonists. These experiments are the
first to investigate the effects of dopaminergic drugs on the facilitation of sign-tracking
engendered by nicotine and they implicate dopaminergic systems both in conditioned approach as
well as the incentive-promoting effects of nicotine.
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1. Introduction1
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Nicotine, one of the most widely used addictive substances in the world (Ague, 1972,
Lerman and Audrain-McGovern, 2010), is considered to be the reinforcing agent in tobacco
products (USDHHS, 1988). Several lines of evidence suggest that nicotine plays a critical
role in smoking and other forms of tobacco use (Chaudhri et al., 2006, Rose, 2006, Caggiula
et al., 2009, Le Foll and Goldberg, 2009). Nicotine supports operant behavior in humans
(Perkins et al., 2001) as well as several non-human species (Henningfield and Goldberg,
1983). Nicotine replacement therapies are one of the most widely used treatments for
smoking cessation and they improve cessation rates by 50–70% (Stead et al., 2012). Also,
cessation products that do not include nicotine or include nicotine reduction (e.g., Quest®
cigarettes) have been commercial failures, whereas smoke-free cigarettes that provide a
nicotine vapor, while not accepted as cessation therapies, are gaining market share as
alternatives to tobacco delivery products (Odum et al., 2012).

Author Manuscript

The central role of nicotine in tobacco dependence is undeniable; however, the role of
nicotine in dependence may not be as straightforward as with other abused drugs. Nicotine is
a moderate stimulant with weak and unreliable reinforcing properties (Caggiula et al., 2009).
While nicotine infusions by themselves support operant behavior in non-human animals
(Donny et al., 2003); the effects of nicotine are weak, and under progressive-ratio
reinforcement schedules the motivation to obtain nicotine infusions is relatively low
(Chaudhri et al., 2007). In choice situations, nicotine is less preferred than other abused
drugs, such as cocaine (Manzardo et al., 2002). Despite its relatively low reinforcing
efficacy, responding for nicotine is robustly enhanced by inclusion of other environmental
stimuli (Palmatier et al., 2006). For example, visual reinforcers included with nicotine
infusions increase operant responding (Donny et al., 2003) and motivation to obtain the
reinforcer(s) (Chaudhri et al., 2007). This interaction between nicotine and non-nicotine
stimuli has recently been replicated in human smokers (Perkins and Karelitz, 2013b, a).
Also, human research suggests that the ‘euphoric’ effects of nicotine self-administered in
cigarettes are weak and their subjective pleasure may be heavily influenced by
environmental factors (Dar et al., 2007) and that individuals with high reactivity to foodassociated cues also have high reactivity to nicotine-associated cues (Mahler and de Wit,
2010).

Author Manuscript

Evidence from our laboratory and others has stressed that incentive motivation may be
critical to the interaction between nicotine and non-nicotine stimuli (Olausson et al., 2004a
2004, Palmatier et al., 2012a, Palmatier et al., 2012b, Peartree et al., 2012). For example, we
recently found that nicotine-induced increases in motivation in an operant task did not
depend on the strength of the reinforcer used, but was exquisitely sensitive to the strength of
1Abbreviations: bHR, bred for high responsiveness to novel environments; bLR, bred for low responsiveness to novel environments;
CS, conditioned stimulus; DA, dopamine; NIC, nicotine; SAL, saline; US, unconditioned stimulus
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the ‘cues’ associated with that reinforcer (Palmatier et al., 2012b). We also found that
nicotine increased approach to a conditioned stimulus (CS) that was spatially separated from
an unconditioned stimulus (US) in a Pavlovian conditioned approach task (Palmatier et al.,
2012a). This increase in ‘sign tracking’ (i.e., approach to CS) was not accompanied by a
change in approach to the US (‘goal tracking’), and the nicotine-induced increase in sign
tracking was systematically related to in the intensity of the US. Specifically, greater
nicotine-induced increases in sign tracking were observed when the CS was paired with 20%
sucrose, relative to rats that had the CS paired with 5% sucrose. Collectively, these findings
suggest that nicotine increases incentive-based motivation, which may help to explain why
the reinforcing (Donny et al., 2003, Chen et al., 2011) and rewarding (Peartree et al., 2012)
effects of nicotine are more robust when non-nicotine reinforcers and rewards are included
in the test paradigm.

Author Manuscript
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Incentive motivation is widely considered to depend on the mesotelencephalic dopamine
(DA) system (Berridge and Robinson, 1998, Wightman and Robinson, 2002, Uslaner et al.,
2008, Flagel et al., 2011, Saunders and Robinson, 2012, Anselme et al., 2013). For example,
in selectively bred rats that display more sign tracking behavior, phasic DA responses to a
CS are more pronounced in the core of the nucleus accumbens (NAc). Systemic
administration of the non-selective DA antagonist flupenthixol reduces acquisition of sign
tracking in these rats (Flagel et al., 2011). Reduced expression of sign tracking was observed
after local administration of flupenthixol to the NAc (Saunders and Robinson, 2012). Also,
genetic reconstruction of D1-receptor function in the NAc core in DA D1 receptor knock-out
mice preferentially increased acquisition of sign-tracking responses, whereas reconstruction
of D1 function in the NAc shell did not restore sign- or goal-directed conditioned responses
(Gore and Zweifel, 2013). Thus, the NAc, and in particular DA D1 receptors in the core,
appear to play a critical role in the acquisition and expression of sign tracking.

Author Manuscript

We hypothesized that nicotine-facilitated sign tracking is dependent on mesolimbic DA
transmission. To address this hypothesis, we replicated our previous findings in which
injections of nicotine prior to testing sessions increase approach to a CS paired with a sweet
reward. In Experiment 1, the CS (30 s presentation of a light) was presented inside of a
receptacle that could monitor approach (head entries). The US (0.1 ml presentation of 5%
chocolate solution) was delivered in a separate, identical receptacle in which head entries
could also be monitored. Once we established that nicotine increased approach to the CS, we
investigated the role of DA receptors by pre-treating rats with the D1 receptor antagonist
SCH-23390, the D2/3 receptor antagonist eticlopride, and the non-selective DA receptor
antagonist flupenthixol. A video-recording system installed in the testing chambers and
automated behavioral monitoring software were used to monitor approach and non-specific
effects of the antagonists. In Experiment 2 the findings from Experiment 1 were confirmed
with a CS that is more comparable to previous studies of sign tracking – a lever was inserted
into the chamber for 30 s and a light above the lever was illuminated. Sucrose solution (20%
w/v) served as the US in Experiment 2.

Pharmacol Biochem Behav. Author manuscript; available in PMC 2015 November 01.
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2. Method
2.1. Subjects
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2.1.1. Experiment 1—Ten male Sprague Dawley rats weighing 274–300 were purchased
from Charles River Laboratories (Raleigh, NC) and were housed in a temperature- and
humidity-controlled environment. The rats were non-naïve, as they initially participated as
control subjects in a previous operant-conditioning experiment with a sucrose reinforcer
(20% w/v). In that study, rats were randomly assigned to NIC (0.4 mg/kg nicotine) or SAL
(vehicle) exposure conditions (n=5/group). Rats in both groups received 24 sessions
(approximately 1 h per day) in the operant test chambers and the NIC group received 26
exposures to nicotine, but these injections were temporally separated from chamber
exposures (at least 1 h after sessions). To reduce generalization between studies, the rats
were shifted to new chambers, the levers were removed, and Nesquick® chocolate was used
as the US. In the original study, sucrose was delivered in a liquid dipper for pressing a lever
located on one wall of the chamber. For the present study, the CS and US locations were on
the opposite wall and Nesquick was delivered via syringe pump to a receptacle well (see
Apparatus). All rats had water ad libitum and were fed 20 g food per day, after the daily
conditioning session.
2.1.2. Experiment 2—Sixteen male Sprague Dawley rats weighing 274–300 were
purchased from Charles River Laboratories (Raleigh, NC) and were housed in the same
manner as Experiment 1. All rats in Experiment 2 were naïve before acquisition.
2.2. Drugs and Solutions

Author Manuscript

Nicotine hydrogen tartrate salt was purchased from Sigma-Aldrich (St. Louis, MO) and
mixed in sterile saline, the pH was adjusted to 7.0 (±0.2) with a dilute NaOH solution.
Nicotine dose (0.4 mg/kg) was calculated from the freebase form and the solution was
injected subcutaneously 15 min before testing sessions unless otherwise noted. SCH-23390,
(−)-eticlopride hydrochloride, and flupenthixol dihydrochloride were purchased from R&D
Systems (Minneapolis, MN) and mixed in sterile saline. All DA antagonists were injected
into the intraperitoneal cavity (ip) 30 min before test sessions. Powdered Nesquick®
(chocolate) was purchased from a local market and dissolved in tap water at a concentration
of 5% (w/v).
2.3. Apparatus

Author Manuscript

Ten standard modular operant chambers housed in sound attenuating cubicles were used in
this experiment. The chambers, cubicles, interfacing and software were purchased from Med
Associates (St Albans, VT). Each chamber had two walls fitted with three modular panels
for intelligence devices. One of the walls was fitted with two receptacles equipped with LED
panel lamps and infrared head-entry detectors, a liquid well and an 18 g pipe for fluid
delivery. In Experiment 1, fluid was delivered to the US receptacle via syringe pump (Razel
Scientific, St. Albans, VT) with a 10 RPM motor, and the syringe was fitted with a blunted
18 g needle and connected to the US receptacle with Tygon chemical resistant microbore
tubing (10.16 mm, ID). The syringe pump was programmed to deliver 0.1 ml of the
Nesquick® solution for each US presentation. The receptacles were located on the left and
Pharmacol Biochem Behav. Author manuscript; available in PMC 2015 November 01.
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center panels of the wall. Because of the size of the head-entry detector units, the height of
each receptacle had to be offset – the left receptacle was mounted slightly lower, with the
bottom edge approximately 1.5 cm above the floor of the chamber, the right receptacle was
higher, with the bottom edge located 6 cm above the floor. The light stimuli were Dialight
LED panel lamps (white, 20 mA, 100 foot-lambert luminous intensity) purchased from
Newark-Element 14 (Newark, NJ). The opposite wall was fitted with a liquid dipper and
head entry receptacle (center panel), two levers and stimulus lights located above each lever
(left and right panels). The lever in the right panel was fitted with a wire that was attached to
a contact lickometer and could record lever contacts. For rats in Experiment 1, the preceding
study included lever-press operants and sucrose delivered via the liquid dipper on this wall.
For rats in Experiment 2, the lever mounted in the right panel and and the stimulus light
directly above it served as the CS.

Author Manuscript
Author Manuscript

Each operant test chamber was fitted with a network surveillance camera (TV-IP572PI,
TrendNet, Torrance, CA) that was mounted to the ceiling of the sound attenuating cubicle
and attached to a local router for data collection. The cameras were equipped with nearinfrared emitters for low-light recordings. Video recordings from CS and pre-CS periods
were triggered by a background procedure written in MED-PC software (Med Associates)
and a local application written by the first author. The background procedure and software
initiated a recording from each network camera by creating an instance of VLC Media
Player (VideoLAN, Paris, France) which was terminated after 30 s. The recording from each
chamber was appended to one of two video files (pre-CS or CS) compiled throughout the
session for each rat. Each video file contained a 10 min compilation of the pre-CS or CS
periods from an entire session. To conserve disk space, video was only recorded during DA
antagonist test sessions and preceding/intervening placebo ‘washout’ tests. Video files were
stored on a local server for later analysis with AnyMaze video tracking software (Harvard
Apparatus, Holliston, MA). Background procedures and locally created software are
available upon request from the first author. VLC Media Player is free, open source software
(www.videolan.org).
2.4. Procedure

Author Manuscript

2.4.1 Experiment 1—To reduce the possibility that prior NIC exposure might alter goal or
sign tracking in our control group, the rats with prior exposure to nicotine were assigned to
the NIC group and received NIC pretreatments 15 min before test sessions. Rats in the SAL
group received placebo injections 15 min before test sessions. Our previous experiments
(Palmatier et al., 2012a) found that prior NIC exposure is not needed to obtain the increases
in sign tracking observed in the present studies. Sessions were conducted on consecutive
days (7 days/week). Each session was 60 min long with 20 trials randomly distributed
throughout each session. For each trial, the CS was illuminated for 30 s and the US was
delivered immediately after CS presentation. Conditioning proceeded as previously
described (Palmatier et al., 2012a); initially both the CS and US were delivered in the left
(lower) receptacle. After robust conditioned approach was established (10 sessions), the US
was shifted to the right (upper) receptacle, however, CS presentations remained in the left
receptacle. Antagonist tests were carried out after stable approach was established with CS
and US presentations in separate receptacles (less than 30% variance in average approach to
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US receptacle in both groups). Rats were tested with SCH-23390, then eticlopride, then
flupenthixol in the order listed. Dose order was randomized and one ‘washout’ session was
given between each antagonist test. Before all non-drug sessions, placebo (saline) was
administered ip 30 min before session onset.

Author Manuscript
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2.4.2 Experiment 2—To confirm the findings of Experiment 1, naïve rats received a more
traditional sign tracking/goal tracking procedure in which insertion of a lever served as the
CS. Rats were randomly assigned to one of two groups (PRE or POST, n=8 per group). For
these rats, nicotine pretreatment began the day before acquisition started (Day 0) and
continued throughout testing. During testing, all rats received two injections – one injection
15 min before testing sessions and one injection in the home cage at least one hour after
testing sessions were completed. For the PRE group, 0.4 mg/kg nicotine injections were
administered 15 min before testing and placebo was administered in the home cage. This
order was reversed in the POST group. This procedure was used to investigate whether
exposure to nicotine outside of the conditioning context (home cage, POST group) promoted
sign-tracking in a manner that was comparable to acute nicotine pretreatment (conditioning
apparatus, PRE group). Before conditioning began, all rats were trained to access 20%
sucrose from a liquid dipper within 5 s in two consecutive sessions, nicotine (PRE) or saline
(POST) injections were administered before these sessions; 1 h after these sessions rats
received the reverse injection. Conditioning was comparable to Experiment 1 in that each
session was 60 min, CS presentations were 30 s in duration, and there were 20 pairings of
the CS and US randomly distributed during the session. However, in Experiment 2 insertion
of the left lever and illumination of the stimulus light above the lever served as the CS and
the US (20% sucrose, w/v) was presented in the liquid dipper for 5 s. After the 21
acquisition sessions, post-session injections were discontinued and all rats received only
their assigned pre-session injection – 0.4 mg/kg NIC for the PRE group and 0.9% saline for
the POST group. Conditioning continued for 5 more sessions to habituate rats to the new
procedures and to reduce the likelihood that post-session nicotine injections would influence
DA antagonist tests. Rats were then tested with SCH-23390 (0.05 mg/kg) or eticlopride (0.1
mg/kg) in randomized order, followed by a combination of both antagonists (0.025 mg/kg
SCH-23390 + 0.05 mg/kg eticlopride). Dose selection was based on the findings of
Experiment 1; two consecutive saline ‘washout’ tests were included between each antagonist
test.
2.5. Data Analyses

Author Manuscript

2.5.1. Elevation and Duration Scores – Experiment 1—Conditioned approach
behavior was quantified using the elevation score, which has been described previously
(Brooks, Besheer et al., 2004, Palmatier et al., 2004). The elevation score is a difference
score calculated by subtracting receptacle entries that occur during the pre-CS period (30 s
before the CS) from receptacle entries that occur during the CS; it quantifies to what degree
receptacle entries during CS presentation are elevated from baseline levels. This measure
has the principal advantage of being continuous, so changes in receptacle entries during the
CS are easily detected compared to ratio or probabilistic transformations in which scaling
can obscure changes in behavior. Inclusion of pre-CS baseline in this measure also accounts
for differences in overall activity, making it a specific measure of conditioned approach. To
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complement the elevation score, the duration of receptacle entries during each CS and preCS was also measured. This temporal measure was converted to a ‘duration score’, which
was calculated in the same way as the elevation score and quantifies how much time spent in
a receptacle during CS presentation is elevated from baseline levels.
2.5.2. Lever contacts and Receptacle Entries – Experiment 2—Because the lever
is not presented during the pre-CS period, approach to the CS in Experiment 2 was
quantified as lever contacts recorded by the contact lickometer during CS presentations and
served as the principal measure of sign tracking. In order to make the measures of
conditioned approach comparable in Experiment 2, US entries (during CS presentation) was
the principal measure of goal tracking.
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2.5.2. Video Tracking—Video was recorded during the pre-CS and CS intervals.
Tracking of each rat was conducted by dividing the chamber image into 5-cm2 grids. A ‘CS
zone’ was operationally defined as a 15 cm × 10 cm grid in front of the left receptacle. A
‘US zone’ the same size was defined in front of the right receptacle. Because of slight
differences in the height of the CS and US, these zones included the visible openings of each
receptacle and wall space above/below each receptacle; therefore they included floor space
which extended approximately 12.2 cm away from the wall containing both receptacles. The
rest of the chamber (not included in the CS and US zones) was considered the ‘neutral zone’
and was used to quantify general activity. Measures of activity included distance traveled
(m) and frequency of grid-line crosses; these measures were based on the center mass of the
subject. Measures of conditioned approach included time spent in each zone and frequency
of zone entries; these were based on the location of the subject’s head in the test chamber.

Author Manuscript
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2.5.3. Statistical Tests—Multivariate analyses of variance (MANOVAs) were used to
determine statistical reliability of the results because our principal dependent measures (sign
tracking and goal tracking) are related. Each approach measure (goal tracking, sign tracking)
was treated as an outcome variable in the analyses and both were included in the Omnibus
model. Univariate tests included in the model were used to parse which outcome(s)
contributed to significant main effects and interactions. Where appropriate, Session or Dose
(DA antagonist dose) served as within-subjects factors/repeated measures, and Drug (e.g.,
NIC vs. SAL) was a between-subjects factor. For antagonist tests, a profile analysis of the
within-subjects factor (Dose) was performed with second-order, simple-effects tests for NIC
and SAL rats comparing the 0 dose (baseline) to sign and goal tracking at each of the
antagonist test doses. For the MANOVAs, Pillai’s trace was used for all significance tests
because it provides the most protection against Type I error with small sample sizes. SPSS
statistical software (IBM, New York) was used to perform significance tests, and
significance was set at an alpha of p≤0.05. For follow-up pairwise contrasts on antagonist
tests, Bonferroni’s method was used to correct for alpha inflation on each measure (sign or
goal tracking), and the critical alpha was set at p≤0.017 (Experiment 1) or p≤0.05
(Experiment 2).
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3. Results
3.1 Experiment 1: Receptacle Entry
3.1.1. Acquisition—During the first 10 sessions, all rats learned to approach the left
receptacle during the CS (Fig. 1). The MANOVA on elevation scores (Fig. 1A) confirmed
that there was a significant main effect of Session [F(18,144)=4.4, p<0.001]. However, the
Drug × Session interaction was not significant (F<1). An identical pattern emerged for
duration scores (Fig. 1C), with significant main effect of Session [F(14,112)=2.6, p<0.01]
but no interaction (F<1). Due to a programming error, duration scores were not calculated
for the right receptacle during the first two acquisition sessions, so these sessions were
eliminated from analyses.
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Shifting the US to the right receptacle resulted in a shift in conditioned approach by both
groups (Fig 1); however, the NIC group maintained high levels of approach to the left (CS)
receptacle, whereas the SAL group reduced approach to the CS during this phase. This was
confirmed by MANOVAs on elevation scores including Session (11–15) as a withinsubjects factor and Drug as a between-subjects factor and side (left-CS, right-US) as
outcome variables. For elevation scores (Fig 1A-B), there was a significant main effect of
Session and a Side × Session interaction [Fs(8,64)≥2.42, p≤0.02]. Second-order, simple
effects contrasting Drug on each dependent variable across trials were used for follow-up
analyses. For goal tracking (elevation scores from the right-US receptacle), these contrasts
were not significant (ps≥0.27). However, for sign tracking (elevation scores from the left-CS
receptacle) there were significant differences between NIC and SAL rats on Sessions 13–15
(ps<0.01). For duration scores, this pattern was not replicated, probably due to the reduction
in time spent in the left receptacle and increase in time spent in the right receptacle that
occurred after the goal switch (Fig. 1C-1D). MANOVA revealed a significant main effect of
Session [F(8,64)=3.21, p=0.004], but the Session × Drug interaction was not significant
(p=0.23). On each measure, there was a significant main effect of Drug [Fs(1,8)≥5.4,
ps<0.05], suggesting that NIC tended to increase time spent in the left (sign) receptacle (Fig.
1C) and reduce time spent in the right (goal) receptacle (Fig. 1D) during these sessions.

Author Manuscript

3.1.2. SCH-23390—The DAD1 antagonist SCH-23390 reduced conditioned behaviors in
all rats, but specifically goal tracking in the SAL group and sign tracking in the NIC group
(Fig 2A-B). The MANOVA confirmed a significant main effect of Dose (SCH dose) as well
as a significant Dose × Drug interaction [Fs(6,48)≥3.4, ps≤0.02] on elevation scores for
receptacle entries. Univariate tests within the model confirmed that SCH-23390 reduced
both goal- and sign-tracking responses (ps<0.01). For NIC rats, the 0.05 and 0.1 mg/kg
SCH-23390 doses significantly reduced sign-tracking entries (ps<0.001), but SCH-23390
did not alter goal tracking entries at any dose for these rats (ps≥0.17). In contrast, for the
SAL rats the 0.05 and 0.1 mg/kg SCH-23390 doses reduced goal tracking entries (ps<0.017)
but did not alter sign tracking entries (ps≥0.1).
For duration scores, there was a similar pattern (Fig 2C-D), with a significant main effect of
Dose and a significant Dose × Drug interaction [Fs(6,48)≥3.6, ps<0.01]. Univariate tests
included in the model confirmed that SCH-23390 reduced the duration of both goal and sign
tracking responses (ps<0.01). Second-order simple contrasts confirmed that SCH-23390
Pharmacol Biochem Behav. Author manuscript; available in PMC 2015 November 01.
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pretreatment (0.05 and 0.1 mg/kg) caused a significant reduction in duration scores for sign
tracking in NIC rats at both doses (ps<0.017), but did not alter goal tracking (ps≥0.17).
SCH-23390 (0.05 and 0.1 mg/kg) significantly reduced duration scores in the goal
receptacle (ps<0.017), relative to the 0 mg/kg baseline for SAL rats. There was also a
significant decrease in duration scores in the sign receptacle for these rats, but only after
pretreatment with 0.05 mg/kg SCH-23390 (p<0.01).
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3.1.3. Video Tracking and Reliability—Three dependent measures (distance traveled
during the Pre-CS, time spent in CS zone, and time spent in US zone) were automatically
calculated by Any-Maze software. Because this measure was novel, reliability analyses were
performed on the CS and US zone time measures from 15 randomly selected video samples.
Manual video scoring was performed by a research assistant who was blind to the
experimental conditions and data sampling. The analyses confirmed that Any-Maze video
analysis was comparable to blind human observation for CS and US zone time (r=0.90) and
CS and US zone entries (r=0.87). One of the video cameras malfunctioned during testing, so
one rat from the SAL group was eliminated from these video tracking analyses (NIC: n=5,
SAL: n=4).
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Video - Approach during the CS: SCH-23390 did not reduce zone time in the goal
location for any group at any dose. However, time spent in the CS zone was reduced at all
SCH-23390 doses (0.01–0.1 mg/kg) for NIC rats, but not for SAL rats (Fig. 2E-F). There
was a significant main effect of Dose, as well as a significant Drug × Dose interaction
[Fs(6,42)≥2.5, ps≤0.04]. Univariate follow-ups confirmed that the main effect of Dose and
the Drug × Dose interaction were both based on changes in the sign-tracking response
[Fs(3,21)≥5.71, ps<0.01]. Second-order, simple contrasts confirmed that 0.01–0.1 mg/kg
SCH-23390 reduced zone time in the CS location for NIC rats (ps≤0.01). SCH-23390 did
not reduce zone time in the goal location for either group (ps≥0.28).

Author Manuscript

Video - Activity during the Pre-CS: To assess drug effects on general locomotor activity,
we analyzed line crossings and distance traveled during the Pre-CS period. NIC pretreatment
increased both measures of activity during the Pre-CS, but SCH-23390 did not reduce basal
activity (SAL groups) or NIC-induced activity in this experiment (Fig. 2G-H). The
MANOVA included both outcome variables (distance traveled and line crossings), as they
are related measures of activity, and revealed a significant main effect of Drug [Fs(1,7)
≥6.26, ps≤0.04], but no main effect of Dose nor a Dose × Drug interaction (ps≥0.14). For
line crossings, MANOVA revealed significant main effects of Drug [F(1,7)=10.88, p=0.01]
and Dose [F(3,21)=3.29, p=0.04]. Line crossings did not significantly differ from the 0
mg/kg dose after any other SCH-23390 dose (ps≥0.42).
3.1.4. Eticlopride—Similar to SCH-23390, the DAD2/3 antagonist eticlopride reduced
goal tracking in the SAL group and sign tracking in the NIC group, but its effect was more
potent in the NIC rats (Fig 3A-B). The MANOVA revealed a significant main effect of Dose
and a significant Dose × Drug interaction [Fs(6,48)≥2.91, ps≤0.02]. Univariate tests
conducted as part of the model revealed that eticlopride reduced approach to both the sign
and goal (ps≤0.02). Second-order, simple contrasts confirmed that eticlopride (0.1–0.2
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mg/kg) reduced sign-tracking (ps≤0.005) but not goal-tracking entries (ps≥0.02) in NIC rats.
In SAL rats, the 0.2 mg/kg dose reduced goal-tracking entries (p=0.005), but none of the
doses altered sign-tracking entries (ps≥0.49).
A comparable effect was observed for duration scores, as the highest dose of eticlopride (0.2
mg/kg) reduced goal tracking in the SAL group and the two highest doses (0.1–0.2 mg/kg)
reduced sign tracking in the NIC group (Fig 3C-D). MANOVA revealed a significant main
effect of Dose and a significant Dose × Drug interaction [Fs(6,48)≥3.99, ps≤0.003]. Secondorder simple contrasts confirmed that the 0.2 mg/kg dose of eticlopride significantly reduced
goal tracking in SAL rats (p=0.005) without affecting sign-tracking duration, and that the
0.1 and 0.2 mg/kg eticlopride doses reduced sign tracking in the NIC rats (ps≤0.001) without
affecting goal-tracking duration.

Author Manuscript

Video – Approach during the CS: Eticlopride (0.2 mg/kg) reduced time spent in the goal
zone for both NIC and SAL rats, but did not alter time spent in the CS zone for either group
(Fig. 3E-F). The omnibus MANOVA revealed only a significant main effect of Dose
[F(6,42)=2.4, p=0.044]. Follow-ups confirmed that this was based on a significant reduction
in goal zone time for rats pretreated with the highest eticlopride dose (p<0.01).

Author Manuscript

Video - Activity during the Pre-CS: Eticlopride did not reduce activity in SAL rats and
only reduced NIC-induced activity at the highest doses (Fig 3G-H). MANOVA on
locomotion revealed a significant main effect of Dose [F(6,42)=5.56, p<0.001] as well as a
significant Dose × Drug interaction [F(6,42)=2.98, p=0.015]. Second-order contrasts
revealed that no dose of eticlopride altered activity in SAL rats (ps≥0.14). However, for NIC
rats, the 0.1 and 0.2 mg/kg eticlopride doses significantly reduced line crossings (ps<0.017),
but only the 0.2 mg/kg dose significantly reduced distance traveled in NIC rats (p=0.01).
3.1.5. Flupenthixol—The highest dose of the non-selective DA antagonist flupenthixol
reduced goal tracking in both NIC and SAL groups. However, all three doses of flupenthixol
reduced sign-tracking in only NIC rats (Fig 4A-B). The MANOVA on elevation scores
confirmed a significant main effect of Dose and a significant Dose × Drug interaction
[Fs(6,48)≥4.02, ps≤0.002], and univariate tests included in the model confirmed that
flupenthixol reduced both sign- and goal-tracking entries (ps<0.001). Second-order, simple
contrasts confirmed that the 0.75 mg/kg dose of flupenthixol significantly reduced goaltracking entries in both NIC and SAL rats (ps≤0.01). However, all three flupenthixol doses
(0.03–0.75 mg/kg) significantly reduced sign-tracking entries in the NIC rats (ps≤0.002)
with no effect on SAL rats.

Author Manuscript

A similar pattern was observed for duration scores; however, this measure was more
sensitive to changes in goal tracking induced by flupenthixol (Fig 4C-D). The MANOVA on
duration of receptacle entries revealed a significant main effect of Dose and a significant
Dose × Drug interaction [Fs(6,48)≥5.3, ps<0.001], and univariate tests included in the model
confirmed that flupenthixol decreased the duration of both the sign- and goal-receptacle
entries during the CS (ps<0.001). Follow-up comparisons confirmed that for SAL rats, 0.5
and 0.75 mg/kg flupenthixol significantly reduced duration scores in the goal location
(ps≤0.002), while the decrease in NIC rats did not reach significance (ps≥0.02, critical alpha
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= 0.017). In contrast, all three doses (0.03–0.75 mg/kg) of flupenthixol significantly reduced
duration scores in the sign location in NIC rats (ps≤0.01), but not SAL rats (ps≥0.03).
Video – Approach during the CS: Flupenthixol reduced approach to the sign at all doses
for the NIC group, but did not alter approach to the sign in the SAL group. In contrast,
flupenthixol only reduced goal tracking in SAL rats, and only at the highest dose tested
(0.75 mg/kg; Fig. 4E-F). The omnibus MANOVA revealed a significant main effect of
Dose, as well as a significant Drug × Dose interaction [Fs(6,42)≥2.74, ps≤0.024]. Secondorder contrasts confirmed that all flupenthixol doses (0.25–0.75 mg/kg) reduced CS zone
time for NIC rats (ps≤0.01); however, flupenthixol did not alter US zone time for this group
(ps ≥0.36). For SAL rats, flupenthixol significantly reduced US zone time (0.75 mg/kg,
p<0.017) but not CS zone time (ps≥0.08).

Author Manuscript

Video – Activity during the Pre-CS: Flupenthixol did not reduce activity in SAL rats and
only reduced NIC-induced activity at the highest doses (Fig 4G-H). MANOVA revealed a
significant Dose × Drug interaction [F(6,42)=2.6, p=0.03]. Second-order contrasts
confirmed that flupenthixol did not reduce activity in SAL rats at any dose (ps≥0.25). For
NIC rats, the two highest doses of flupenthixol (0.5–0.75 mg/kg) reduced distance traveled
(ps<0.017), but none of the flupenthixol doses significantly reduced line-crossings in this
group (p≥0.033, critical alpha = 0.017).
3.3. Experiment 2: Lever Contacts and Receptacle Entries

Author Manuscript

3.3.1. Acquisition—At the end of acquisition testing there were no significant differences
in goal tracking but the PRE group approached the lever CS significantly more than the
POST group (Fig. 5). This was confirmed by MANOVA including both lever contacts (sign
tracking) and receptacle entries (goal tracking) as response variables. There was a significant
effect of Group [F(2,13)=21.2, p<0.001] and univariate tests included in the model
confirmed that this effect was based on a significant difference in lever contacts
[F(1,14)=12.9, p<0.01] but not receptacle entries (p=0.16).

Author Manuscript

3.3.2. SCH-23390—SCH-23390 (0.05 mg/kg) reduced goal tracking (Fig. 6a) and sign
tracking (Figure 6b) in rats pretreated with nicotine (PRE group) and significantly reduced
goal tracking (Fig. 6a) in rats pretreated with saline (POST group). MANOVA revealed
significant main effects of Group and Dose, as well as a significant Group × Dose
interaction [Fs(2,13)≥4.8, ps≤0.027]. Univariate follow-ups confirmed that the main effect
of SCH-23390 pretreatment was based on reductions of both lever contacts and receptacle
entries [Fs(1,14)≥9.3, ps<0.01]. The Drug × Dose interaction was based primarily on
reductions in lever-contacts in the PRE group [F(1,14)=8.6, p=0.011]. Second-order, simple
contrasts confirmed that 0.05 mg/kg SCH-23390 reduced receptacle entries for POST rats
(p<0.05) but not PRE rats (p=0.14) and reduced lever contacts for PRE rats (p<0.001), but
not POST rats (p=0.47).
3.3.3. Eticlopride—Eticlopride (0.1 mg/kg) reduced goal tracking in both groups (Fig. 6a)
but did not significantly alter sign-tracking (Fig. 6b). MANOVA revealed significant main
effects of Group and Dose [Fs(2,13)≥11.9, ps≤0.01], but the Group × Dose interaction did
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not reach statistical significance (p=0.63). Univariate follow-ups confirmed that the main
effect of eticlopride pretreatment (Dose) was based on reductions of receptacle entries
[F(1,14)=24.8, p<0.001] but not changes in lever contacts (F<1). Second-order, simple
contrasts confirmed that 0.1 mg/kg eticlopride reduced receptacle entries for both PRE and
POST groups (ps≤0.002).

Author Manuscript

3.3.4. SCH-23390 and Eticlopride Cocktail—The mixture of SCH-23390 (0.025
mg/kg) and eticlopride (0.05 mg/kg) reduced goal tracking in both groups (Fig. 6a) but only
reduced sign-tracking in rats that were pretreated with nicotine (PRE group, Fig. 6b).
MANOVA revealed significant main effects of Group and Dose as well as a significant
Group × Dose interaction [Fs(2,13)≥5.5, ps≤0.02]. Univariate follow-ups confirmed that the
Group × Dose interaction was based on reductions in lever contacts [F(1,14)=16.4, p<0.001]
but not changes in receptacle entries (p=0.23). Second-order, simple contrasts confirmed
that the SCH-23390 and eticlopride cocktail reduced receptacle entries for both PRE and
POST groups (ps≤0.014), whereas lever contacts were only reduced in the PRE group
(p<0.001).

4. Discussion

Author Manuscript
Author Manuscript

The present studies confirm our previous findings (Palmatier et al., 2012a) that nicotine
promotes approach to a CS (sign tracking) which is spatially separated from the US, but has
only marginal effects on approach to the US (goal tracking). These studies also implicate
dopaminergic systems in the incentive-promoting effects of nicotine; systemic pretreatments
with both selective and non-selective DA receptor antagonists reduced the facilitation of
sign-tracking engendered by nicotine. Surprisingly, the antagonists selectively reduced signtracking behaviors in nicotine pretreated rats but reduced goal-tracking behaviors in saline
pretreated rats. The findings of Experiment 2 add a second confirmation (see Palmatier et
al., 2012a) that the facilitation of sign-tracking by nicotine does not depend on acquisition
procedures (e.g., shifting the location of the US). In addition, Experiment 2 demonstrates
that nicotine-induced increases in sign-tracking are observed using the more traditional
lever-CS paradigm. An important additional component of these studies was the
measurement of locomotion within the chamber by using video recordings, and the distance
and line-crossing data confirmed that the DA antagonists had marginal effects on basal
activity in the operant test chambers (SAL groups). Although eticlopride and flupenthixol
both reduced measures of nicotine-induced hyperactivity at the highest doses tested, these
reductions were not always associated with reductions in conditioned approach. Thus, the
reductions in incentive motivation observed in the present study cannot be explained by
simple motor suppressant effects of the antagonists. These experiments are the first to
investigate the effects of dopaminergic drugs on the facilitation of sign-tracking engendered
by nicotine.
The present studies confirm that the dopamine system is critically involved in the increased
sign tracking observed in rats pretreated with nicotine. Several previous studies have
implicated mesotelencephalic DA systems in behavioral responses to nicotine including
primary reinforcement (Corrigall et al., 1992, Corrigall et al., 1994), locomotor sensitization
(Palmatier and Bevins, 2002, Sheppard et al., 2009), and conditioned place-preference
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(Acquas et al., 1989). DA antagonists also reduce effects of nicotine that may be related to
its incentive-promoting effects. For example, the ability of nicotine to reduce current
threshold on intracranial self-stimulation is blocked by the non-selective DA antagonist
haloperidol (Ivanova and Greenshaw, 1997). Surprisingly, very little attention has been paid
to the role of dopamine systems in the ‘reinforcement-enhancing’ or incentive-amplifying
effects of nicotine (Olausson et al., 2004a, b, Liu et al., 2007a, Liu et al., 2007b, Palmatier et
al., 2008). Among the many reasons that researchers have avoided investigating
dopaminergic drugs in operant tasks is the fact that DA systems are critically involved in
primary reinforcement by multiple rewards including food (Sharf et al., 2005), brain
stimulation (Phillips and Fibiger, 1979) and access to a receptive mate (Pfaus and Phillips,
1991). Moreover, DA antagonists can impair motor function when they are administered
systemically (Hoffman and Beninger, 1985).
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In the paradigm employed in Experiments 1–2, we were better equipped to describe the
topography of conditioned approach responses – including both the frequency and duration
of receptacle entries and using measures that take baseline levels of receptacle entry into
account (the elevation and duration scores). In addition, the video-tracking system allowed
us to examine gross changes in activity as well as approach to the receptacles that may have
been below the threshold of the receptacle-entries (time spent in proximity to the CS and US
receptacles). By including these measures, we could dissociate the effects of the DA
antagonists on approach behavior from their effects on gross activity – confirming that D1,
D2/3, and non-selective DA antagonists reduced the facilitation of sign tracking engendered
by nicotine. In addition, an important dissociation between the receptacle entry and videotracking findings emerged. Both D1 and D2/3 antagonists reduced entries into the sign
receptacle for NIC pretreated rats and reduced entries into the goal receptacle for SAL
pretreated rats. However, video-tracking data suggest that SCH-23390 preferentially reduced
sign tracking in NIC rats (Figure 5A), whereas eticlopride only reduced goal tracking in
SAL rats (Figure 6B). These observations suggest the possibility of a dissociation between
DA receptor subtypes in some aspects of the topography of conditioned approach behaviors;
however, additional data are needed for confirmation. One potential reason that the DA
antagonists did not reduce sign tracking in saline-pretreated rats is a ‘floor effect’ – basal
approach to the CS was so low it would be difficult to measure reductions. However, this
conclusion may follow from presentation of the data, in which approach is averaged across
all trials and not summed across the session. For example, basal approach to the CS in
saline-pretreated rats included approximately 40 lever contacts per session in Experiment 2.
Thus, a floor effect seems to be an unlikely account for the selective effects of the DA
antagonists.

Author Manuscript

Sign-tracking is receiving increasing attention in pre-clinical models of substance use
disorders because of its apparent critical association with incentive motivation and
mesotelencephalic DA systems (Saunders and Robinson, 2013). Studies in awake, behaving
rats suggest that phasic DA release is associated with the delivery of unexpected rewards
(Mirenowicz and Schultz, 1996), reward-predictive CSs (Schultz, 1998b, a, Phillips et al.,
2003, Roitman et al., 2004), and salient sensory stimuli (Robinson et al., 2002, Robinson
and Wightman, 2004). However, the DA release that is time-locked to presentation of
incentives (Day et al., 2007, Brown et al., 2011) and is robust in sign-tracking rats (Flagel et
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al., 2011) has been almost exclusively observed in the NAc core, which has been extensively
linked to Pavlovian approach behavior (Parkinson et al., 1999, Di Ciano et al., 2001,
Parkinson et al., 2002, Dalley et al., 2005). Systemic administration of flupenthixol blocked
the acquisition of sign-tracking in rats that were selectively-bred for high responsiveness to
novel environments (bHR rats) (Flagel et al., 2011), and local infusion of flupenthixol into
the NAc core reduced the expression of sign tracking (Saunders and Robinson, 2012).
Similarly, the present data found that systemic flupenthixol dose-dependently dampened the
expression of sign-tracking in rats that showed NIC-enhanced sign-tracking behavior.
Extending these results, SCH-23390 and eticlopride also dose-dependently reduced signtracking behavior in these rats, indicating that both D1- and D2-type receptor activation
contribute to conditioned approach to the CS.
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Although learning of cue-reward associations that lead to goal-tracking behavior is
dopamine-independent, the expression of the goal-tracking response seems to be dopamine
dependent. In the present study, flupenthixol, SCH-23390 and eticlopride reduced goaltracking behavior in SAL rats, albeit with generally less potency than their effects on signtracking, indicating that both conditioned responses are sensitive to DA receptor blockade at
doses that do not produce non-specific motor effects. These findings are consistent with
Flagel and colleagues (2011), who investigated the effects of flupenthixol on the acquisition
vs. expression of Pavlovian conditioned approach in bHR (sign-tracking) or bLR (goaltracking) rats. Goal tracking was reduced by pretreatment with flupenthixol during
acquisition in bLR rats. However, in a subsequent ‘drug-free’ expression test goal tracking
recovered to control levels. This finding demonstrates that global antagonism of DA
receptors disrupts expression of the conditioned response, without altering acquisition of the
associations that lead to the conditioned response. The site of DA action in goal tracking
may be specific; when flupenthixol was infused directly into the NAc core, only minimal
reductions in approach to the goal were observed in bLR rats (Saunders and Robinson,
2012). Finally, the necessity of DA signaling may differ in the acquisition of sign- versus
goal-tracking behavior. Based on the above and current studies, we can conclude that while
DA signaling contributes to the expression of both sign-tracking and goal-tracking approach,
different neural learning circuits support their acquisition and different cortico-striatal
pathways support their expression.

Author Manuscript

One of the difficulties in distinguishing the neural substrates of sign- and goal-tracking is
that both behaviors involve approach to stimuli with incentive properties. The goal is a
spatial stimulus with an ambiguous meaning – reward (US) is delivered only at that
receptacle but infrequently; most of the time no reward is available in the goal location. The
CS is a spatio-temporal stimulus with a discrete meaning – at the end of the CS, a reward is
always delivered. The temporal properties of the CS may be critical to the development of
sign tracking, as previous studies have shown that inserting a trace between the CS and US
delivery reduces sign-tracking (Christian et al., 1983). Mesotelencephalic DA systems have
frequently been implicated in timing behavior, as mice with deletions of the gene that
encodes the DA transporter display poor temporal control of behavior in operant timing
tasks (Meck et al., 2012) and the firing of DA neurons in the VTA shifts from ‘surprising’
rewards to CSs that temporally disambiguate reward delivery (Schultz et al., 1997, Schultz,

Pharmacol Biochem Behav. Author manuscript; available in PMC 2015 November 01.

Palmatier et al.

Page 15

Author Manuscript

1998b, a). Thus, an important feature of the sign-tracking approach response may be the
discrete temporal nature of the CS and the responsiveness of incentive systems to temporal
stimuli. For example, drugs that facilitate phasic DA release or mimic the effects of DA at
post-synaptic receptors may increase attention to temporally discrete incentives. Although
more research is needed to investigate this hypothesis, the temporal features of sign-stimuli
have been basically ignored in the recent resurgence of sign-tracking studies (cf. Christian et
al., 1983). Nevertheless, the goal-tracking response is also time-locked to the presentation of
the CS, with the critical difference being the target of the conditioned approach. This may be
why DA receptor antagonists diminished the expression of conditioned sign-tracking or goal
tracking responses in the present experiment, depending on what the animal exhibited at
baseline.
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The procedures used in Experiment 1 diverge somewhat from the more traditional
procedures currently used in sign tracking experiments that investigate ‘incentive salience’
(Saunders and Robinson, 2012, Anselme et al., 2013). The two principal differences are (1)
use of spatially distinct receptacles as the sign and goal and (2) shifting of the US from the
sign receptacle to the goal receptacle. The rationale for using two receptacles is to equate
response form – a lever stimulus evokes grasping, manipulation, and biting behaviors
(Tomie et al., 2008), whereas a receptacle evokes exploratory behavior (Holland, 1979)
which includes sniffing and licking at the fluid well (Bueno and Moreira, 1998). Thus,
comparisons of approach behaviors are more direct. Although some investigators have
suggested that the difference in response forms may make the behaviors qualitatively
distinct (Berridge et al., 2009), this assertion has never been empirically confirmed. In fact,
evidence from sexual conditioning studies in male Japanese Quail suggests that when signs
and goals are similar (e.g., species typical cues used as signs) the sign tracking CR is more
robust and more resistant to extinction (Krause et al., 2003). The rationale for shifting the
location of the goal was prompted by an insight from one of our previous studies (Palmatier
et al., 2012a) in which the sign was originally presented in the same location as the goal. We
realized that we had very little control over what is actually learned about the spatial cues
(e.g., receptacle, light location, etc.). Lights presented in different spatial locations may be
easily discriminated (e.g., Floresco et al., 2008); therefore we felt that the best way to ensure
that the sign maintained its full status as an excitatory CS was by moving the goal location
while leaving the sign stimuli unaltered – thus any configuration between the temporal
features of the light illumination and spatial cues remained intact. Although it is tempting to
consider that nicotine may have specifically altered extinction of goal tracking in
Experiment 1, such an assertion is problematic for two reasons. First, ‘extinction’ refers to
attenuation of a conditioned response that is observed when the CS is presented but the US
is withheld. In Experiment 1, US presentation is not withheld and the CS is still a temporal
predictor of the US, but is no longer an accurate spatial cue. Thus, one would have to assert
that nicotine impaired extinction of spatially-specific conditioned approach responses. This
seems an overly complex hypothesis, especially in light of the evidence from Experiment 2
(present studies) and our previous research (Palmatier et al., 2012a) which show that
nicotine increases sign tracking when signs and goals are spatially separate from the start of
acquisition. The extinction hypothesis is less parsimonious than the hypothesis that nicotine
simply increased sign tracking.
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In summary, the present studies confirm the role of DA in NIC-induced enhancement of sign
tracking to a CS. Moreover, they establish that both D1- and D2-type receptor activation
contributes to conditioned approach to the CS in sign-tracking rats and to the US location in
goal-tracking rats, although these receptor effects may occur in different striatal subregions.
These findings further our understanding of NIC augmentation of non-drug reinforcement
that contributes to the neurobiological mechanism of nicotine addiction.
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Highlights
•

Nicotine increased approach to sucrose-paired conditioned stimuli (sign
tracking).

•

Systemic administration of dopaminergic antagonists was investigated.

•

A dopamine D1 antagonist reduced facilitation of sign tracking by nicotine.

•

A dopamine D2/3 receptor selective antagonist reduced approach to the reward
location.

•

The facilitation of sign tracking by nicotine depends on dopamine D1 receptor
signaling.
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Figure 1.
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Panels A and B illustrate elevation scores (the frequency of receptacle entries during the CS
minus the frequency of receptacle entries during the Pre-CS period) over acquisition tests in
the receptacles on left (A) and right (B) side of the chamber. Panels C and D illustrate
duration scores (duration of entries during the CS minus duration of entries during the
PreCS) for the same receptacles and sessions. During the first 10 sessions, both the CS and
US were presented in the receptacle on the left side of the chamber and all rats learned to
approach the CS, as illustrated by elevation (A) and duration (C) scores above 0. For
sessions 11–15, the US was presented in the receptacle on the right side; while all rats
learned to approach this receptacle during CS presentations (B, D), rats pretreated with
nicotine (NIC group) made more approach responses in the CS receptacle (Left, A).
*Indicates a significantly higher elevation score for NIC group relative to SAL group,
p<0.01.
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Figure 2.

SCH-23390 reduced goal-tracking in rats pretreated with saline (SAL group) and reduced
sign-tracking in rats pretreated with nicotine (NIC group). Panels A and B illustrate
elevation scores (the frequency of receptacle entries during the CS minus the frequency of
receptacle entries during the Pre-CS period) as a function of SCH-23390 dose. Panels C and
D illustrate duration scores (duration of entries during CS-PreCS) across SCH-23390 doses.
The abscissa displays dose on a log scale. SCH-23390 reduced time spent in CS zone (G)
only in rats pretreated with nicotine, without altering other measures of conditioned
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approach or locomotion. Panels E and F illustrate the effects of SCH-23390 on locomotion;
distance traveled (E) and line crossings (F) during Pre-CS intervals served as general
measures of activity. Panels G and H illustrate the effects of SCH-23390 on additional
measures of conditioned approach behavior: time spent in CS (G) and US (H) zones during
the CS intervals. The abscissa displays dose on a log scale. *Indicates that SCH-23390
significantly reduced behavior in NIC group, relative to placebo (0mg/kg),
p<0.017. #Indicates a significant reduction in conditioned approach for SAL rats, relative to
placebo (0mg/kg SCH-23390), p<0.017.
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Figure 3.

Eticlopride reduced goal-tracking in rats pretreated with saline (SAL group) and reduced
sign-tracking in rats pretreated with nicotine (NIC group). Panels A and B illustrate
elevation scores (the frequency of receptacle entries during the CS minus the frequency of
receptacle entries during the Pre-CS period) as a function of eticlopride dose. Panels C and
D illustrate duration scores (duration of entries during CS-PreCS) across eticlopride doses.
The abscissa displays dose on a log scale. Eticlopride dose-dependently reduced activity in
rats pretreated with nicotine (NIC group), but did not reduce activity in rats pretreated with
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saline (SAL group). Eticlopride did not alter time spent in the CS zone but the highest
eticlopride dose reduced time spent in the US zone in in both groups. Panels E and F
illustrate the effects of eticlopride on additional measures of conditioned approach behavior;
time spent in CS and US zones during the CS intervals (E and F, respectively). Panels G and
H illustrate the effects of eticlopride on locomotion; distance traveled (G) and line crossings
(H) during Pre-CS intervals served as general measures of activity. The abscissa displays
dose on a log scale. ^Indicates eticlopride significantly reduced behavior in NIC and SAL
groups, relative to placebo (0mg/kg), p<0.017. *Indicates that eticlopride significantly
reduced behavior in NIC group, relative to placebo (0mg/kg), p<0.017. #Indicates a
significant reduction in conditioned approach for SAL rats, relative to placebo (0mg/kg
eticlopride), p<0.017.
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Figure 4.

Flupenthixol (FLU) reduced goal-tracking in all rats, but only reduced sign-tracking in rats
pretreated with nicotine (NIC group). Panels A and B illustrate elevation scores (the
frequency of receptacle entries during the CS minus the frequency of receptacle entries
during the Pre-CS period) as a function of FLU dose. Panels C and D illustrate duration
scores (duration of entries during CS-PreCS) across FLU doses. The abscissa displays dose
on a log scale. Flupenthixol (FLU) significantly reduced distance traveled in rats pretreated
with nicotine (NIC group), but did not significantly reduce line crossings in either group. All
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doses of FLU reduced time spent in the CS zone in NIC rats, while the highest dose reduces
time spent in the US zone in SAL rats. Panels E and F illustrate the effects of FLU on
additional measures of conditioned approach behavior: time spent in CS and US zones
during the CS intervals (E and F, respectively). Panels G and H illustrate the effects of FLU
on locomotion; distance traveled (G) and line crossings (H) during Pre-CS intervals served
as general measures of activity. The abscissa displays dose on a log scale. *Indicates that
FLU significantly reduced behavior in NIC group, relative to placebo (0mg/kg),
p<0.017. #Indicates that FLU significantly reduced behavior in SAL group, relative to
placebo (0mg/kg), p<0.017.
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Figure 5.

In Experiment 2 pretreatment with nicotine increased approach to the lever-CS, but did not
alter approach to the US receptacle. Receptacle entries during CS presentation are plotted on
the left ordinate, lever contacts during CS presentation are plotted on the right ordinate. The
bars represent the average number of approach responses to each location for each rat on the
final three acquisition sessions (19–21). *indicates significantly more lever contacts for the
PRE group, relative to the POST group, p<0.05.
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Figure 6.

In Experiment 2, the selective DA D1 antagonist SCH-23390 (0.05 mg/kg) reduced goal
tracking in the POST group (Panel A) and sign-tracking in the PRE group (Panel B). The
DA D2/3 antagonist eticlopride (0.1 mg/kg) reduced goal tracking in both the PRE and
POST groups (Panel A), but had no effect on sign tracking. The combination of both
SCH-23390 (0.025 mg/kg) and eticlopride (0.05 mg/kg) had summative effects on approach
– goal tracking was reduced in both groups and sign tracking was only reduced in the PRE
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group. *indicates significantly fewer approach responses after antagonist pretreatment,
relative to placebo control pretreatment, p<0.05.
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